A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer

Abstract

Purpose: To explore the clinical application value of indocyanine green (ICG)–rituximab in sentinel lymph node biopsy. Methods: This study included 156 patients with primary breast cancer: 50 patients were enrolled in dose-climbing test, and 106 patients were enrolled in verification test. This was to compare the consistency of ICG–rituximab and combined method in the detected lymph nodes. Results: According to the verification test, the imaging rate of ICG–rituximab was 97.3%. Compared with the combined method, the concordance rate of fluorescence method was 0.991 (28 + 78/107; p < 0.001). Conclusion: For ICG–rituximab as a fluorescent targeting tracer, the optimal imaging dose of ICG 93.75 μg/rituximab 375 μg can significantly reduce the imaging of secondary lymph nodes. Compared with the combined method, it has a higher concordance rate.

Keywords: :

• breast cancer
• dose-climbing test
• fluorescent targeting tracer
• ICG
• ICG–rituximab
• rituximab
• sentinel lymph node
• SLNB
• tracer
• verification test

Author contributions

QS Zhang, PP Li and S Wu were responsible for study conception and design. X Sun, BB Cong and YS Wang were responsible for acquisition of data and analysis. S Wu, PP Li and YS Wang were responsible for drafting of the manuscript. All authors were responsible for interpretation of data/results and revision of the manuscript.

Financial disclosure

This work was supported by Hebei Medical Science Research Project (20220190). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/